Citations (40)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Jinmiao Lu, Yicong Bian, Hua Zhang, Dong Tang, Xusheng Tian, Xinyi Zhou, Zengyan Xu, Yating Xiong, Zheming Gu, Zhenwen Yu, Tong Wang, Juping Ding, Qiang Yu & Jinsong Ding. (2022) The metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C] cetagliptin in healthy volunteers. Xenobiotica 52:1, pages 38-45.
Read now
Read now
Andrew Bryson, Paul E Jennings, Laszlo Deak, Fraga S Paveliu & Matt Lawson. (2016) The efficacy and safety of teneligliptin added to ongoing metformin monotherapy in patients with type 2 diabetes: a randomized study with open label extension. Expert Opinion on Pharmacotherapy 17:10, pages 1309-1316.
Read now
Read now
Takashi Kadowaki, Fuyuhiko Marubayashi, Shoko Yokota, Makoto Katoh & Hiroaki Iijima. (2015) Safety and efficacy of teneligliptin in Japanese patients with type 2 diabetes mellitus: a pooled analysis of two Phase III clinical studies. Expert Opinion on Pharmacotherapy 16:7, pages 971-981.
Read now
Read now
Ryuichi Morishita & Hironori Nakagami. (2015) Teneligliptin: expectations for its pleiotropic action. Expert Opinion on Pharmacotherapy 16:3, pages 417-426.
Read now
Read now
Shuji Kinoshita & Kazuoki Kondo. (2015) Evaluation of pharmacokinetic and pharmacodynamic interactions of canagliflozin and teneligliptin in Japanese healthy male volunteers. Expert Opinion on Drug Metabolism & Toxicology 11:1, pages 7-14.
Read now
Read now
Theodosios D Filippatos, Vasilios G Athyros & Moses S Elisaf. (2014) The pharmacokinetic considerations and adverse effects of DDP-4 inhibitors. Expert Opinion on Drug Metabolism & Toxicology 10:6, pages 787-812.
Read now
Read now
Articles from other publishers (34)
Makiko Shimizu, Miaki Makiguchi, Yuka Yokota, Erika Shimamura, Moegi Matsuta, Yuria Nakamura, Mizuki Harano & Hiroshi Yamazaki. (2023) Simple confirmation methods for rare but impaired variants of human flavin-containing monooxygenase 3 (FMO3) found in an updated genome resource databank. Drug Metabolism and Pharmacokinetics 53, pages 100528.
Crossref
Crossref
Anna Gumieniczek & Anna Berecka-Rycerz. (2023) Metabolism and Chemical Degradation of New Antidiabetic Drugs (Part II): A Review of Analytical Approaches for Analysis of Gliptins. Biomedicines 11:7, pages 1956.
Crossref
Crossref
Miaki Makiguchi, Makiko Shimizu, Yuka Yokota, Erika Shimamura, Eiji Hishinuma, Sakae Saito, Masahiro Hiratsuka & Hiroshi Yamazaki. (2023) Variants of Flavin-Containing Monooxygenase 3 Found in Subjects in an Updated Database of Genome Resources. Drug Metabolism and Disposition 51:7, pages 884-891.
Crossref
Crossref
Yaochen Xie, Qian Zhou, Qiaojun He, Xiaoyi Wang & Jincheng Wang. (2023) Opportunities and challenges of incretin-based hypoglycemic agents treating type 2 diabetes mellitus from the perspective of physiological disposition. Acta Pharmaceutica Sinica B 13:6, pages 2383-2402.
Crossref
Crossref
Hiroshi Yamazaki & Makiko Shimizu. (2023) Species Specificity and Selection of Models for Drug Oxidations Mediated by Polymorphic Human Enzymes. Drug Metabolism and Disposition 51:1, pages 123-129.
Crossref
Crossref
Makiko Shimizu, Akane Yamamoto, Miaki Makiguchi, Erika Shimamura, Yuka Yokota, Mizuki Harano & Hiroshi Yamazaki. (2023) A family study of compound variants of flavin-containing monooxygenase 3 (FMO3) in Japanese subjects found by urinary phenotyping for trimethylaminuria. Drug Metabolism and Pharmacokinetics, pages 100490.
Crossref
Crossref
Yasuhiro Uno, Makiko Shimizu, Yurie Ogawa, Miaki Makiguchi, Hiroaki Kawaguchi, Osamu Yamato, Mayumi Ishizuka & Hiroshi Yamazaki. (2022) Molecular and functional characterization of flavin-containing monooxygenases in pigs, dogs, and cats. Biochemical Pharmacology 202, pages 115125.
Crossref
Crossref
Shailesh Kulkarni & Vaishali Y. Londhe. (2022) Development and evaluation of extended release metformin pellets suspended in teneligliptin jelly for the treatment of diabetes mellitus. Journal of Drug Delivery Science and Technology 70, pages 103192.
Crossref
Crossref
Gianluca Catucci, Gianfranco Gilardi & Sheila J. Sadeghi. 2022. Comprehensive Pharmacology. Comprehensive Pharmacology
509
562
.
Jin-Woo Park, Kyoung-Ah Kim, Jong-Min Kim, In-Hwan Park & Ji-Young Park. (2021) Influence of FMO3 and CYP3A4 Polymorphisms on the Pharmacokinetics of Teneligliptin in Humans. Frontiers in Pharmacology 12.
Crossref
Crossref
Suma Elumalai, Udayakumar Karunakaran, Jun Sung Moon & Kyu Chang Won. (2020) High glucose-induced PRDX3 acetylation contributes to glucotoxicity in pancreatic β-cells: Prevention by Teneligliptin. Free Radical Biology and Medicine 160, pages 618-629.
Crossref
Crossref
Jin‐Woo Park, Kyoung‐Ah Kim & Ji‐Young Park. (2019) Development of a liquid chromatography/tandem‐mass spectrometry assay for the simultaneous determination of teneligliptin and its active metabolite teneligliptin sulfoxide in human plasma. Biomedical Chromatography 34:2.
Crossref
Crossref
Namyi Gu, Sang-In Park, Hyewon Chung, Xuanyou Jin, SeungHwan Lee & Tae-Eun Kim. (2020) Possibility of pharmacokinetic drug interaction between a DPP-4 inhibitor and a SGLT2 inhibitor. Translational and Clinical Pharmacology 28:1, pages 17.
Crossref
Crossref
Shruti Surendran, Rekha Sapkal, David Paul & Satheeshkumar Nanjappan. (2020) Effect of resveratrol on dipeptidyl peptidase-4 inhibitors pharmacokinetics: An in vitro and in vivo approach. Chemico-Biological Interactions 315, pages 108909.
Crossref
Crossref
Jin‐Woo Park, Kyoung‐Ah Kim, Yun Jung Choi, Soo Hyun Yoon & Ji‐Young Park. (2019) Effect of glimepiride on the pharmacokinetics of teneligliptin in healthy Korean subjects. Journal of Clinical Pharmacy and Therapeutics 44:5, pages 720-725.
Crossref
Crossref
Maryam Rameshrad, Bibi Marjan Razavi, Gordon A. A. Ferns & Hossein Hosseinzadeh. (2019) Pharmacology of dipeptidyl peptidase-4 inhibitors and its use in the management of metabolic syndrome: a comprehensive review on drug repositioning. DARU Journal of Pharmaceutical Sciences 27:1, pages 341-360.
Crossref
Crossref
Antonio Ceriello, Valeria De Nigris, Hiroaki Iijima, Takahiro Matsui & Maki Gouda. (2019) The Unique Pharmacological and Pharmacokinetic Profile of Teneligliptin: Implications for Clinical Practice. Drugs 79:7, pages 733-750.
Crossref
Crossref
Takumi Minezumi, Shin-ichi Takeda, Yusuke Igarashi, Kentaro Sato, Yoshiaki Murakami & Daisuke Nagata. (2018) Hypoglycemic Coma in a Hemodialysis Patient Receiving Blood Glucose-Lowering Therapy With the Single Agent Teneligliptin. Clinical Medicine Insights: Case Reports 11, pages 117954761876335.
Crossref
Crossref
Kenichi Tanaka, Yosuke Okada, Hiroko Mori, Yoshifumi Inada, Kanako Suzuka, Kohei Uriu & Yoshiya Tanaka. (2016) Efficacy of linagliptin and teneligliptin for glycemic control in type 2 diabetic patients with chronic kidney disease: assessment by continuous glucose monitoring; a pilot study. Diabetology International 7:4, pages 368-374.
Crossref
Crossref
Eiji Kutoh, Asuka Wada & Sayaka Terayama. (2016) Teneligliptin, a Chemotype Prolyl-Thiazolidine-Based Novel Dipeptidyl Peptidase-4 Inhibitor with Insulin Sensitizing Properties. Clinical Drug Investigation 36:10, pages 809-818.
Crossref
Crossref
C. F. Deacon & H. E. Lebovitz. (2016) Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas. Diabetes, Obesity and Metabolism 18:4, pages 333-347.
Crossref
Crossref
Yoshinobu Nakamaru, Fumihiko Akahoshi, Hiroaki Iijima, Noriko Hisanaga & Toshiyuki Kume. (2016) Tissue distribution of teneligliptin in rats and comparisons with data reported for other dipeptidyl peptidase‐4 inhibitors. Biopharmaceutics & Drug Disposition 37:3, pages 142-155.
Crossref
Crossref
Shinichiro Kimura, Toyoshi Inoguchi, Toshihide Yamasaki, Mayumi Yamato, Makoto Ide, Noriyuki Sonoda, Kenichi Yamada & Ryoichi Takayanagi. (2016) A novel DPP-4 inhibitor teneligliptin scavenges hydroxyl radicals: In vitro study evaluated by electron spin resonance spectroscopy and in vivo study using DPP-4 deficient rats. Metabolism 65:3, pages 138-145.
Crossref
Crossref
Manish Maladkar, Srividya Sankar & Kushal Kamat. (2016) Teneligliptin: Heralding Change in Type 2 Diabetes. Journal of Diabetes Mellitus 06:02, pages 113-131.
Crossref
Crossref
Chihiro Moriya & Hiroaki Satoh. (2016) Teneligliptin Decreases Uric Acid Levels by Reducing Xanthine Dehydrogenase Expression in White Adipose Tissue of Male Wistar Rats. Journal of Diabetes Research 2016, pages 1-9.
Crossref
Crossref
Noritsugu Wada, Katsuhito Mori, Chie Nakagawa, Jun Sawa, Yasuro Kumeda, Tetsuo Shoji, Masanori Emoto & Masaaki Inaba. (2015) Improved glycemic control with teneligliptin in patients with type 2 diabetes mellitus on hemodialysis: Evaluation by continuous glucose monitoring. Journal of Diabetes and its Complications 29:8, pages 1310-1313.
Crossref
Crossref
Lesley J. Scott. (2015) Teneligliptin: A Review in Type 2 Diabetes. Clinical Drug Investigation 35:11, pages 765-772.
Crossref
Crossref
Xiao-Wu Chen, Zhi-Xu He, Zhi-Wei Zhou, Tianxin Yang, Xueji Zhang, Yin-Xue Yang, Wei Duan & Shu-Feng Zhou. (2015) Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus. Clinical and Experimental Pharmacology and Physiology 42:10, pages 999-1024.
Crossref
Crossref
Yoshinobu Nakamaru, Yoshiharu Hayashi, Martin Davies, Horst Jürgen Heuer, Noriko Hisanaga & Kei Akimoto. (2015) Investigation of Potential Pharmacokinetic Interactions Between Teneligliptin and Metformin in Steady-state Conditions in Healthy Adults. Clinical Therapeutics 37:9, pages 2007-2018.
Crossref
Crossref
Yoshinobu Nakamaru, Chie Emoto, Makiko Shimizu & Hiroshi Yamazaki. (2015) Human pharmacokinetic profiling of the dipeptidyl peptidase-IV inhibitor teneligliptin using physiologically based pharmacokinetic modeling. Biopharmaceutics & Drug Disposition 36:3, pages 148-162.
Crossref
Crossref
Makiko Shimizu, Arisa Shiraishi, Ayumi Sato, Satomi Nagashima & Hiroshi Yamazaki. (2015) Potential for drug interactions mediated by polymorphic flavin-containing monooxygenase 3 in human livers. Drug Metabolism and Pharmacokinetics 30:1, pages 70-74.
Crossref
Crossref
Tomomi Taniguchi-Takizawa, Makiko Shimizu, Toshiyuki Kume & Hiroshi Yamazaki. (2015) Benzydamine N-oxygenation as an index for flavin-containing monooxygenase activity and benzydamine N-demethylation by cytochrome P450 enzymes in liver microsomes from rats, dogs, monkeys, and humans. Drug Metabolism and Pharmacokinetics 30:1, pages 64-69.
Crossref
Crossref
Miho Yamazaki, Makiko Shimizu, Yasuhiro Uno & Hiroshi Yamazaki. (2014) Drug oxygenation activities mediated by liver microsomal flavin-containing monooxygenases 1 and 3 in humans, monkeys, rats, and minipigs. Biochemical Pharmacology 90:2, pages 159-165.
Crossref
Crossref
Yoshinobu Nakamaru, Yoshiharu Hayashi, Mana Sekine, Shuji Kinoshita, Jeff Thompson, Atsuhiro Kawaguchi, Martin Davies, Horst Jürgen Heuer, Hiroshi Yamazaki & Kei Akimoto. (2014) Effect of Ketoconazole on the Pharmacokinetics of the Dipeptidyl Peptidase-4 Inhibitor Teneligliptin: An Open-Label Study in Healthy White Subjects in Germany. Clinical Therapeutics 36:5, pages 760-769.
Crossref
Crossref